[Interferon in the treatment of multiple myeloma].
R. Kuzmits(University of Vienna), Werner Scheithauer(Comprehensive Cancer Center Vienna), B.G. Van Camp, H. Ludwig(Universitätsmedizin Göttingen), E Polli(European Institute of Oncology), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), R. Flener(Fraunhofer Austria)
PubMed
January 1, 1985
Cited by 3
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
|Journal of Clinical Oncology|2009|643